The information that I will be sharing is from preliminary and limited experience. I recently gave a lecture to physicians about my 10 year experience with LDN therapy in 1100 patients. I added a case study of a patient with sarcoidosis at the end of the lecture that made two doctors come up and talk to me with excitement. One was a primary care doctor who had a sarcoidosis patient who he was really concerned about. She kept getting readmitted to the hospital for pulmonary infections or with difficulty breathing. He pleaded for me to see her and do a consultation in the morning. Another physician was a nephrologist who sees many renal disease patients who suffer from sarcoidosis and he understood the potential mechanisms of action of LDN with the underlying T-cell inflammatory cell changes seen in sarcoidosis.
The patient that I presented in the lecture is a 70 year old African American with sarcoidosis for over 30 years. She was referred to me as a gastroenterologist owing to having a CT scan showing enlargement of the liver, multiple lesions in the spleen and enlargement of the lymph nodes which had previously been biopsied showing sarcoidosis. The largest splenic lesion was increasing in size. The liver and spleen had multifocal hypo- attenuating lesions. The radiologist read the CT scan abnormality as most likely being due to the known history of sarcoidosis but cancer needed to be excluded. I received the notes and referral prior to seeing the patient in the office so I had a chance to really think what I was going to offer her when she came in for consultation. With the enlarged liver I could have her go through a liver biopsy but if the liver lesions were due to cancer no treatment would be curable.
Ever since learning about LDN and manipulation of uncontrolled inflammation, I became intrigued – basically starting with an open mind and thinking about diseases and syndromes of unknown causes was a thrilling situation to be in. With many of the diseases and syndromes that been explored for LDN therapy, the common theme is taking control of unregulated inflammation.
The patient was treated with 4.5 mg naltrexone daily and she noted a decrease in her fatigue, improvement in breathing and she was able to stop antibiotic therapy for a chronic painful facial rash. A follow up CT scan 7 months after treatment showed a decrease in the size of splenic lesions and lymph nodes. The liver still had numerous tiny lesions but they were decreased in number. My plan is to continue the LDN and observe her clinical course.